- Home
- RGLS vs ALLK Comparison
RGLS vs ALLK Comparison
Compare RGLS & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- ALLK
- Stock Information
- Founded
- RGLS 2007
- ALLK 2012
- Country
- RGLS United States
- ALLK United States
- Employees
- RGLS N/A
- ALLK N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- RGLS Health Care
- ALLK Health Care
- Exchange
- RGLS Nasdaq
- ALLK Nasdaq
- Market Cap
- RGLS 106.7M
- ALLK 58.0M
- IPO Year
- RGLS 2012
- ALLK 2018
- Fundamental
- Price
- RGLS $1.59
- ALLK $1.24
- Analyst Decision
- RGLS Strong Buy
- ALLK Hold
- Analyst Count
- RGLS 6
- ALLK 5
- Target Price
- RGLS $10.33
- ALLK $1.67
- AVG Volume (30 Days)
- RGLS 391.3K
- ALLK 1.1M
- Earning Date
- RGLS 11-11-2024
- ALLK 11-11-2024
- Dividend Yield
- RGLS N/A
- ALLK N/A
- EPS Growth
- RGLS N/A
- ALLK N/A
- EPS
- RGLS N/A
- ALLK N/A
- Revenue
- RGLS N/A
- ALLK N/A
- Revenue This Year
- RGLS N/A
- ALLK N/A
- Revenue Next Year
- RGLS N/A
- ALLK N/A
- P/E Ratio
- RGLS N/A
- ALLK N/A
- Revenue Growth
- RGLS N/A
- ALLK N/A
- 52 Week Low
- RGLS $1.08
- ALLK $0.54
- 52 Week High
- RGLS $3.79
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- RGLS 53.16
- ALLK 65.99
- Support Level
- RGLS $1.39
- ALLK $1.18
- Resistance Level
- RGLS $1.68
- ALLK $1.48
- Average True Range (ATR)
- RGLS 0.12
- ALLK 0.16
- MACD
- RGLS 0.01
- ALLK 0.05
- Stochastic Oscillator
- RGLS 68.97
- ALLK 69.41
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.